DMAC
NASDAQ HealthcareDiaMedica Therapeutics Inc. - Common Stock
Biotechnology
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
�� 市场数据
| 价格 | $6.85 |
|---|---|
| 成交量 | 212,296 |
| 市值 | 369.10M |
| 贝塔系数 | 1.150 |
| RSI（14日） | 51.3 |
| 200日均线 | $6.91 |
| 50日均线 | $7.41 |
| 52周最高 | $10.42 |
| 52周最低 | $3.33 |
| Forward P/E | -8.19 |
| Price / Book | 6.56 |
🎯 投资策略评分
DMAC 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (81/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 🐋 Institutional Whale (9/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 DMAC in your text
粘贴任何文章、记录或帖子 — 工具将提取 DMAC 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.